Licochalcone A exerts antitumor activity in bladder cancer cell lines and mice models

Tropical Journal of Pharmaceutical Research

Volumn 15, Issue 6, 2016, Pages 1151-1157

  Zhang, Yue Yang ^a   Huang, Chang Ting ^a   Liu, Shao Ming ^b   Wang, Bin ^c   Guo, Jun ^d   Bai, Jian Qi ^a   Fan, Xiao Jing ^e   Jia, Yu Sen ^c  

^a WANGJING HOSPITAL   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE THIRD AFFILIATED HOSPITAL   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^e National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion   (China)

Author keywords

Bladder carcinoma; Cell proliferation; Interferon; Licochalcone A; Phosphorylation; Splenocytes

Indexed keywords

ALPHA INTERFERON; LICOCHALCONE A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL LINE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; MTT ASSAY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; WESTERN BLOTTING;

EID: 84977574442     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: 10.4314/tjpr.v15i6.6     Document Type: Article

References (22)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Hiss DC, Gabriels GA. Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part I: targeting p53, Mdm2, GADD153/CHOP, GRP78/BiP and heat shock proteins. Expert Opin. Drug Discov 2009; 4: 799-821.
3. Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
4. Zachos I, Konstantinopoulos PA, Tzortzis V. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin Investig Drugs 2010; 19: 875-887.
5. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005; 4: 677-685.
6. Gollob JA, Wilhelm S, Carter C. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33: 392-406.
7. Mendel DB, Laird AD, Xin X. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
8. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490.
9. Nowakowska Z. A review of anti-infective and antiinflammatory chalcones. Eur J Med Chem 2007; 42: 125-137.
10. Go ML, Wu X, Liu XL. Chalcones: An update on cytotoxic and chemoprotective properties. Curr Med Chem 2005; 12: 483-499.
11. Kumar D, Kumar NM, Akamatsu K, Kusaka E, Harada H, Ito T. Synthesis and biological evaluation of indolyl chalcones as antitumor agents. Bioorg Med Chem Lett 2011; 20: 3916-3919.
12. Sivakumar PM, Ganesan S, Veluchamy P, Doble M. Novel chalcones and 1, 3, 5-triphenyl-2-pyrazoline derivatives as antibacterial agents. Chem Biol Drug Des 2010; 76: 407-411.
13. Sakai T, Eskander RN, Guo Y, Kim KJ, Mefford J, Hopkins J, Bhatia NN, Zi X, Hoang BH. Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines. J Orthop Res 2011; 30: 1045-1050.
14. Chimenti F, Fioravanti R, Bolasco A, Chimenti P, Secci D, Rossi F. Chalcones: A valid scaffold for monoamine oxidases inhibitors. J Med Chem 2009; 52: 2818-2824.
15. Lust S, Vanhoecke B, Janssens A, Philippe J, Bracke M, Offner F. Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res 2005; 49: 844-850.
16. Lyndsay V. R, Syreeta L. T, Stephen M. B, Shuchen W, Hafez A K, Shannon E. M, Melyssa R. B, Qiang Z, Guangdi W, Matthew E. B, Bridgette M. C-B. Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer. Oncology lett. 2012; 3: 163-171.
17. Zachos I, Konstantinopoulos PA, Tzortzis V. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin Investig Drugs 2010; 19: 875-887.
18. Jeong EK, Lee SY, Jeon HM. Role of extracellular signalregulated kinase (ERK)1/2 in multicellular resistance to docetaxel in MCF-7 cells. Int J Oncol 2010; 37: 655-661.
19. Peng DJ, Wang J, Zhou JY. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun 2010; 394: 600-605.
20. Frumento G, Piazza T, Di Carlo E. Targeting tumorrelated immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 2006; 6: 233-237.
21. Molldrem JJ, Lee PP, Wang C. Evidence that specific T lymphocytes may participate in the elimination of chronic myelo-genous leukemia. Nat Med 2000; 6: 1018-1023.
22. Von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6: 338-344.